Weight Gain on Glucose-Lowering Agents

摘要: Ninety percent of type 2 diabetes patients are obese or overweight at diagnosis. Obesity is a major risk factor for cardiovascular disease. Weight reduction beneficial in improving glycemic control and reducing risk. Some glucose-lowering drugs associated with significant weight gain potential, particularly insulin, insulin secretagogues, thiazolidinediones. antidiabetic medication can aggravate risk, be detrimental to control, reduces drug adherence compliance by patients. In this chapter, the effect on potential will reviewed mechanisms discussed. Therapeutic regimens known offset drug-induced highlighted.